NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
4.270
-0.430 (-9.15%)
At close: Nov 4, 2025, 4:00 PM EST
4.369
+0.099 (2.31%)
After-hours: Nov 4, 2025, 7:59 PM EST
NovaBridge Biosciences Employees
NovaBridge Biosciences had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$1,249,688
Market Cap
492.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | -188 | -85.45% |
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | 185 | 51 | 38.06% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Microsoft | 228,000 |
| Apple | 166,000 |
| Oracle | 162,000 |
| SAP SE | 109,973 |
| Cisco Systems | 86,200 |
| Taiwan Semiconductor Manufacturing Company | 83,825 |
| ASML Holding | 44,027 |
| Broadcom | 37,000 |
NBP News
- 6 days ago - NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries - GlobeNewsWire
- 6 days ago - I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform - GlobeNewsWire
- 13 days ago - I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 - GlobeNewsWire
- 18 days ago - I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript - Seeking Alpha
- 19 days ago - I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences - GlobeNewsWire
- 21 days ago - I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference - GlobeNewsWire
- 7 weeks ago - I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market - Seeking Alpha
- 2 months ago - I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - GlobeNewsWire